| Umairullah Lodhi, MD | |
|
1350 Hickory St, Melbourne, FL 32901-3224 | |
| (321) 549-0677 | |
| Not Available |
| Full Name | Umairullah Lodhi |
|---|---|
| Gender | Male |
| Speciality | Interventional Radiology |
| Experience | 10 Years |
| Location | 1350 Hickory St, Melbourne, Florida |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356761175 | NPI | - | NPPES |
| 110946300 | Medicaid | FL | |
| PENDING | Other | FL | MEDICARE HF |
| Facility Name | Location | Facility Type |
|---|---|---|
| New York University Langone Medical Center | New york, NY | Hospital |
| Adventhealth Sebring | Sebring, FL | Hospital |
| Adventhealth Tampa | Tampa, FL | Hospital |
| Adventhealth Wesley Chapel | Wesley chapel, FL | Hospital |
| Florida Hospital Zephyrhills | Zephyrhills, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sheridan Radiology Services Of West Florida Inc | 4082998075 | 82 |
| New York University | 1355232422 | 4431 |
| Sheridan Radiology Services Of West Florida Inc | 4082998075 | 82 |
| Mori Bean And Brooks Inc | 8820077878 | 633 |
News Archive
The company behind a pioneering stem cell bandage, believed to be the world's first adult and autologous (patient's own) stem cell treatment designed to heal torn meniscal cartilage, can now take the technology to human clinical trials thanks to an investment from one of the UK's most successful entrepreneurs.
The Senate Finance Committee put the final touches on its healthcare bill early Friday morning, and soon Democratic leaders will begin reconciling it with a more costly alternative approved by the Senate's health panel.
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in adults with attention deficit/hyperactivity disorder (ADHD). TC-5619 is a novel small molecule that is highly selective for the alpha7 neuronal nicotinic receptor, which Targacept refers to as NNR, and was discovered by Targacept scientists using Targacept's proprietary drug discovery platform known as Pentad (TM).
Alzheimer's disease (AD) progresses inside the brain in a rising storm of cellular chaos as deposits of the toxic protein, amyloid-beta (Aβ), overwhelm neurons. An apparent side effect of accumulating Aβ in neurons is the fragmentation of the Golgi apparatus, the part of the cell involved in packaging and sorting protein cargo including the precursor of Aβ. But is the destruction the Golgi a kind of collateral damage from the Aβ storm or is the loss of Golgi function itself part of the driving force behind Alzheimer's? This was the question for Yanzhuang Wang, Gunjan Joshi, and colleagues at the University of Michigan, Ann Arbor, as they set out to uncover the mechanism damaging the Golgi, using a transgenic mouse and tissue culture models of AD to look at what was going on.
› Verified 3 days ago
| Entity Name | Brevard Physician Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598008955 PECOS PAC ID: 1850535048 Enrollment ID: O20130909000619 |
News Archive
The company behind a pioneering stem cell bandage, believed to be the world's first adult and autologous (patient's own) stem cell treatment designed to heal torn meniscal cartilage, can now take the technology to human clinical trials thanks to an investment from one of the UK's most successful entrepreneurs.
The Senate Finance Committee put the final touches on its healthcare bill early Friday morning, and soon Democratic leaders will begin reconciling it with a more costly alternative approved by the Senate's health panel.
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in adults with attention deficit/hyperactivity disorder (ADHD). TC-5619 is a novel small molecule that is highly selective for the alpha7 neuronal nicotinic receptor, which Targacept refers to as NNR, and was discovered by Targacept scientists using Targacept's proprietary drug discovery platform known as Pentad (TM).
Alzheimer's disease (AD) progresses inside the brain in a rising storm of cellular chaos as deposits of the toxic protein, amyloid-beta (Aβ), overwhelm neurons. An apparent side effect of accumulating Aβ in neurons is the fragmentation of the Golgi apparatus, the part of the cell involved in packaging and sorting protein cargo including the precursor of Aβ. But is the destruction the Golgi a kind of collateral damage from the Aβ storm or is the loss of Golgi function itself part of the driving force behind Alzheimer's? This was the question for Yanzhuang Wang, Gunjan Joshi, and colleagues at the University of Michigan, Ann Arbor, as they set out to uncover the mechanism damaging the Golgi, using a transgenic mouse and tissue culture models of AD to look at what was going on.
› Verified 3 days ago
| Entity Name | Sheridan Radiology Services Of West Florida Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235674904 PECOS PAC ID: 4082998075 Enrollment ID: O20170413000678 |
News Archive
The company behind a pioneering stem cell bandage, believed to be the world's first adult and autologous (patient's own) stem cell treatment designed to heal torn meniscal cartilage, can now take the technology to human clinical trials thanks to an investment from one of the UK's most successful entrepreneurs.
The Senate Finance Committee put the final touches on its healthcare bill early Friday morning, and soon Democratic leaders will begin reconciling it with a more costly alternative approved by the Senate's health panel.
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in adults with attention deficit/hyperactivity disorder (ADHD). TC-5619 is a novel small molecule that is highly selective for the alpha7 neuronal nicotinic receptor, which Targacept refers to as NNR, and was discovered by Targacept scientists using Targacept's proprietary drug discovery platform known as Pentad (TM).
Alzheimer's disease (AD) progresses inside the brain in a rising storm of cellular chaos as deposits of the toxic protein, amyloid-beta (Aβ), overwhelm neurons. An apparent side effect of accumulating Aβ in neurons is the fragmentation of the Golgi apparatus, the part of the cell involved in packaging and sorting protein cargo including the precursor of Aβ. But is the destruction the Golgi a kind of collateral damage from the Aβ storm or is the loss of Golgi function itself part of the driving force behind Alzheimer's? This was the question for Yanzhuang Wang, Gunjan Joshi, and colleagues at the University of Michigan, Ann Arbor, as they set out to uncover the mechanism damaging the Golgi, using a transgenic mouse and tissue culture models of AD to look at what was going on.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Umairullah Lodhi, MD 3300 S Fiske Blvd, Rockledge, FL 32955-4306 Ph: () - | Umairullah Lodhi, MD 1350 Hickory St, Melbourne, FL 32901-3224 Ph: (321) 549-0677 |
News Archive
The company behind a pioneering stem cell bandage, believed to be the world's first adult and autologous (patient's own) stem cell treatment designed to heal torn meniscal cartilage, can now take the technology to human clinical trials thanks to an investment from one of the UK's most successful entrepreneurs.
The Senate Finance Committee put the final touches on its healthcare bill early Friday morning, and soon Democratic leaders will begin reconciling it with a more costly alternative approved by the Senate's health panel.
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in adults with attention deficit/hyperactivity disorder (ADHD). TC-5619 is a novel small molecule that is highly selective for the alpha7 neuronal nicotinic receptor, which Targacept refers to as NNR, and was discovered by Targacept scientists using Targacept's proprietary drug discovery platform known as Pentad (TM).
Alzheimer's disease (AD) progresses inside the brain in a rising storm of cellular chaos as deposits of the toxic protein, amyloid-beta (Aβ), overwhelm neurons. An apparent side effect of accumulating Aβ in neurons is the fragmentation of the Golgi apparatus, the part of the cell involved in packaging and sorting protein cargo including the precursor of Aβ. But is the destruction the Golgi a kind of collateral damage from the Aβ storm or is the loss of Golgi function itself part of the driving force behind Alzheimer's? This was the question for Yanzhuang Wang, Gunjan Joshi, and colleagues at the University of Michigan, Ann Arbor, as they set out to uncover the mechanism damaging the Golgi, using a transgenic mouse and tissue culture models of AD to look at what was going on.
› Verified 3 days ago
David Samuel Epstein, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1775 W Hibiscus Blvd, Ste 215, Melbourne, FL 32901 Phone: 321-837-3820 | |
Thomas H Magee, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 709 S Harbor City Blvd Ste 100, Melbourne, FL 32901 Phone: 321-409-9900 Fax: 321-309-9033 | |
Dr. Irina S Mezheritskiy, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1350 S Hickory St, Holmes Regional Medical Center/radiology, Melbourne, FL 32901 Phone: 321-434-7313 Fax: 321-434-7238 | |
Dr. Charles Ehlenberger, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1350 Hickory Street, Melbourne, FL 32901 Phone: 321-434-7000 | |
Dr. Santiago Jimenez, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1223 Gateway Dr, Melbourne, FL 32901 Phone: 321-549-0677 | |
Steven D Picerne, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1800 W Hibiscus Blvd Ste 100, Melbourne, FL 32901 Phone: 321-726-3800 | |
Dr. Brent D Brandon, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1350 S Hickory St, Holmes Regional Medical Center/radiology, Melbourne, FL 32901 Phone: 321-434-7313 Fax: 321-434-7238 |